MRSA Decolonization in Complicated Carriage

Recruiting now · Not applicable

Conditions studied: MRSA

In brief

Multicenter open-label cluster randomized controlled trial determining the superiority of doxycycline-rifampicin compared to trimethoprim-rifampicin for the decolonization treatment of complicated MRSA carriership.

Key facts

Study ID

NCT05268120

Run by

Leiden University Medical Center

People needed

211

Starts

2022-07-25

Expected to finish

2028-05-01

Last updated by the study team

2025-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Complicated MRSA carriership. Complicated carriership is defined as having one of the following features: (i) the presence of MRSA located at another site than the nose, (ii) an active infection with MRSA, (iii) in vitro resistance for mupirocin, (iv) active skin lesions, (v) foreign material that connects an internal body site with the outside (e.g., urine catheter, external fixation material), (vi) previously failure of decolonization treatment.
• In case of none of the previously mentioned features, this is considered uncomplicated carriership.
• The ability to provide informed consent for the use of their data.

You may not qualify if…

• - Presence of any iv-access, urinary catheters or drains (because of high risk of treatment failure)
• Failure of previous decolonization attempt of complicated MRSA carriage
• Allergy or other contra-indication to either doxycycline, rifampicin or trimethoprim (these patients will participate in the observational arm)
• Previous participation in this study (every patient can only participate once)
• Pregnancy

Where it is running

• LUMC — Leiden, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.